BTIG Reiterates Buy Rating on Rapport Therapeutics (RAPP): "see the X-TOLE2 readout as having no readthrough"
Tweet Send to a Friend
BTIG analyst Kambiz Yazdi reiterated a Buy rating and $47.00 price target on Rapport Therapeutics (NASDAQ: RAPP)The analyst commented, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
